$ALXO

ALX Oncology Holdings Inc. (ALXO) has filed its definitive proxy statement (DEF 14A) for its 2026 annual stockholders' meeting, to be held virtually on June 10, 2026. Stockholders will vote on the election of three Class III directors, an advisory "say-on-pay" resolution for named executive officer compensation, and the ratification of KPMG LLP as the independent registered public accounting firm. The filing also details executive compensation, including base salaries, cash incentives, and equity awards, along with information on director independence, board structure, and related-party transactions.